

A reassessment of the role of B7-1 expression in tumor r

Journal of Experimental Medicine

182, 1415-1421

DOI: [10.1084/jem.182.5.1415](https://doi.org/10.1084/jem.182.5.1415)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Triggering of Natural Killer Cells by the Costimulatory Molecule CD80 (B7-1). <i>Immunity</i> , 1996, 5, 311-317.	14.3	220
2	Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1. <i>Molecular Medicine</i> , 1996, 2, 545-555.	4.4	54
3	Genetic approaches to cancer immunotherapy. , 1996, 129, 1-49.		14
4	Granulocyte-macrophage colony-stimulating factor and the immune system. <i>Medical Oncology</i> , 1996, 13, 133-140.	2.5	55
5	Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. <i>Tissue Antigens</i> , 1996, 48, 242-254.	1.0	19
6	Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. <i>European Journal of Immunology</i> , 1996, 26, 1273-1277.	2.9	114
7	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996, 26, 1335-1341.	2.9	135
8	Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. <i>European Journal of Immunology</i> , 1996, 26, 2304-2309.	2.9	115
9	Immunotherapy II: Antigens, receptors and costimulation. <i>Cancer and Metastasis Reviews</i> , 1996, 15, 329-349.	5.9	8
10	Surface Expression of CD28 Single Chain Fv for Costimulation by Tumor Cells. <i>Immunological Reviews</i> , 1996, 153, 209-223.	6.0	18
11	Expression of Co-Stimulatory Molecules by Tumor Cells Decreases Tumorigenicity but May Also Reduce Systemic Antitumor Immunity. <i>Human Gene Therapy</i> , 1996, 7, 1771-1779.	2.7	34
12	Antitumor Responses Induced by Transgenic Expression of CD40 Ligand. <i>Human Gene Therapy</i> , 1997, 8, 1935-1943.	2.7	64
13	Enhanced Immunogenicity of B Cell Lymphoma Genetically Engineered to Express Both B7-1 and Interleukin-12. <i>Human Gene Therapy</i> , 1997, 8, 2217-2228.	2.7	29
14	Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth. <i>Journal of the National Cancer Institute</i> , 1997, 89, 428-436.	6.3	67
15	Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 10889-10894.	7.1	141
16	Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse—Human Glioblastoma Multiforme Model. <i>Human Gene Therapy</i> , 1997, 8, 1073-1085.	2.7	66
17	Irradiated NC Adenocarcinoma Cells Transduced with Both B7.1 and Interleukin-2 Induce CD4+-Mediated Rejection of Established Tumors. <i>Human Gene Therapy</i> , 1997, 8, 477-488.	2.7	33
18	Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. <i>Life Sciences</i> , 1997, 60, 2035-2041.	4.3	41

#	ARTICLE	IF	CITATIONS
19	The Promise and Reality of Cancer Gene Therapy. American Journal of Human Genetics, 1997, 61, 785-789.	6.2	23
20	Immunological Gene Therapy Approaches for Malignant Melanoma. Skin Pharmacology and Physiology, 1997, 10, 105-125.	2.5	12
21	Gene transfer of costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Therapy, 1997, 4, 726-735.	4.5	45
22	Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnology, 1997, 15, 641-646.	17.5	209
23	Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations. Pathology and Oncology Research, 1997, 3, 164-176.	1.9	1
24	Targeting an anti-viral CD8 + T cell response to a growing tumor facilitates its rejection. Cancer Immunology, Immunotherapy, 1997, 44, 230-238.	4.2	17
25	Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. European Journal of Immunology, 1997, 27, 1657-1662.	2.9	16
26	Vaccination as immunotherapy for B cell lymphoma. , 1997, 15, 129-139.		9
27	GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. , 1997, 73, 556-561.		24
28	Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Therapy, 1998, 5, 223-232.	4.5	63
29	Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Therapy, 1998, 5, 1355-1362.	4.5	37
30	Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Therapy, 1998, 5, 1447-1454.	4.5	25
31	Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. British Journal of Cancer, 1998, 78, 1043-1050.	6.4	15
32	Enhancement of the anti-tumor immune response using a combination of interferon- γ and B7 expression in an experimental mammary carcinoma. , 1998, 77, 107-113.		47
33	Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. European Journal of Immunology, 1998, 28, 780-786.	2.9	58
34	The threshold for autoimmune T cell killing is influenced by B7-1. European Journal of Immunology, 1998, 28, 949-960.	2.9	40
35	Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunology, Immunotherapy, 1998, 46, 283-292.	4.2	19
36	NK CELL RECEPTORS. Annual Review of Immunology, 1998, 16, 359-393.	21.8	1,553

#	ARTICLE	IF	CITATIONS
37	GENE THERAPY FOR MELANOMA IN HUMANS. Hematology/Oncology Clinics of North America, 1998, 12, 519-538.	2.2	9
38	The role of B7-CD28 co-stimulation in tumor rejection. International Immunology, 1998, 10, 791-797.	4.0	28
39	Cancer vaccine development. Expert Opinion on Investigational Drugs, 1998, 7, 1439-1452.	4.1	2
40	Co-expression of B7-1 with Interleukin-12 Enhances Vaccine-induced Antitumour Immunity in Experimental Myeloma. Hematology, 1998, 3, 365-374.	1.5	2
41	CD40 and CD70 Co-Stimulate a Potent In Vivo Antitumor T Cell Response. Journal of Immunotherapy, 1998, 21, 225.	2.4	44
42	Interleukin-12-Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. Blood, 1998, 91, 196-206.	1.4	75
43	Progress in Cancer Gene Therapy. Acta Oncologica, 1999, 38, 675-683.	1.8	35
44	The role of herpes simplex virus thymidine kinase in the treatment of solid tumours. Expert Opinion on Investigational Drugs, 1999, 8, 777-785.	4.1	3
45	Anti-Tumor Immunity Elicited by a Recombinant Vaccinia Virus Expressing CD70 (CD27L). Human Gene Therapy, 1999, 10, 1095-1103.	2.7	62
46	Co-stimulatory molecules B7-1 and B7-2 as experimental therapeutic targets. Expert Opinion on Therapeutic Targets, 1999, 3, 93-108.	1.0	1
47	Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. Journal of Experimental Medicine, 1999, 190, 355-366.	8.5	951
48	Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Clinical and Experimental Immunology, 1999, 117, 84-91.	2.6	33
49	Interaction Between B.7 and CD28 Costimulatory Molecules is Essential for the Activation of Effector Function Mediating Spontaneous Tumour Regression. Scandinavian Journal of Immunology, 1999, 49, 633-640.	2.7	9
50	Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28. Immunology, 1999, 97, 280-286.	4.4	8
51	Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunological Reviews, 1999, 172, 131-152.	6.0	95
52	Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Therapy, 1999, 6, 195-208.	4.6	7
53	Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line. Cancer Immunology, Immunotherapy, 1999, 47, 257-264.	4.2	5
54	T cell mediated immunotherapy for B cell lymphoma. Journal of Molecular Medicine, 1999, 77, 322-331.	3.9	24

#	ARTICLE	IF	CITATIONS
55	Growth of human fetal retinal pigment epithelium as microspheres. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 241-248.	1.9	12
56	Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. , 1999, 82, 714-720.		42
57	Expression of Costimulatory Molecules CD80 and/or CD86 by a Kaposi's Sarcoma Tumor Cell Line Induces Differential T-Cell Activation and Proliferation. Clinical Immunology, 1999, 91, 345-353.	3.2	17
58	ThÃ©rapie gÃ©nÃ©rique en cancÃ©rologie : l'attente des rÃ©sultats cliniques. Annales De L'Institut Pasteur / ActualitÃ©s, 1999, 10, 313-325.	0.1	0
59	Gene Therapy in Oncology: Current Technical and Clinical Status of Development. Oncology Research and Treatment, 1999, 22, 11-16.	1.2	2
60	Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. , 2000, 86, 725-730.		64
61	Differential requirement of perforin and IFN-Î³ in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. European Journal of Immunology, 2000, 30, 2507-2515.	2.9	45
62	Costimulatory wars: the tumor menace. Current Opinion in Immunology, 2000, 12, 589-596.	5.5	69
63	Local versus systemic interleukin-2: Tumor formation by wild-type and B7-1-positive murine melanoma cells. Cancer Gene Therapy, 2000, 7, 207-214.	4.6	9
64	Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Therapy, 2000, 7, 144-150.	4.6	12
65	B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Therapy, 2000, 7, 993-999.	4.5	19
66	The role of CD40 in peripheral T cell tolerance and immunity. Journal of Molecular Medicine, 2000, 78, 363-371.	3.9	67
67	Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunology, Immunotherapy, 2000, 49, 85-93.	4.2	10
68	Significance and Regulation of the Expression of MHC Class II Molecules on Autoimmune and Neoplastic Thyroid Cells. , 2000, , 317-335.		1
69	Glioma Immunology and Immunotherapy. Neurosurgery, 2000, 46, 778-792.	1.1	118
70	CD27-Mediated Activation of Murine NK Cells. Journal of Immunology, 2000, 164, 1741-1745.	0.8	119
71	Clinical Protocol: A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma. Albert Einstein Center, Bronx, New York.. Human Gene Therapy, 2000, 11, 1065-1082.	2.7	18
72	Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells. Immunobiology, 2000, 202, 339-352.	1.9	7

#	ARTICLE	IF	CITATIONS
73	Advances in specific immunotherapy of malignant melanoma. Journal of the American Academy of Dermatology, 2000, 43, 167-188.	1.2	43
74	Therapeutic Vaccination for Cancer. Clinical Immunology, 2000, 95, S44-S62.	3.2	62
75	B16 as a Mouse Model for Human Melanoma. Current Protocols in Immunology, 2000, 39, Unit 20.1.	3.6	298
76	Enhancement of natural killer cell-mediated cytotoxicity by coexpression of GM-CSF/B70 in hepatoma. Cancer Letters, 2001, 166, 33-40.	7.2	8
77	POTENT ANTITUMOR EFFECTS OF CD154 TRANSDUCED TUMOR CELLS IN EXPERIMENTAL BLADDER CANCER. Journal of Urology, 2001, 166, 1093-1097.	0.4	41
78	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 2001, 97, 1809-1816.	1.4	201
79	Dendritic cells and immunotherapy for malignant disease. British Journal of Haematology, 2001, 112, 874-887.	2.5	58
80	Decreased generation of anti-tumor immunity after intrasplenic immunization. European Journal of Immunology, 2001, 31, 1392-1399.	2.9	9
81	Peripheral Blood Dendritic Cells, but Not Monocyte-Derived Dendritic Cells, Can Augment Human NK Cell Function. Cellular Immunology, 2001, 213, 14-23.	3.0	28
82	B7.1 expression eliminates tumor resistance to IL-12 gene therapy. Cancer Gene Therapy, 2001, 8, 118-127.	4.6	8
83	Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma. Cancer Gene Therapy, 2001, 8, 361-370.	4.6	33
84	The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Therapy, 2001, 8, 580-588.	4.6	38
85	Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature, 2001, 411, 1058-1064.	27.8	469
87	Large Nontransplanted Hepatocellular Carcinoma in Woodchucks: Treatment With Adenovirus-Mediated Delivery of Interleukin 12/B7.1 Genes. Journal of the National Cancer Institute, 2001, 93, 472-479.	6.3	61
88	B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo. Journal of Experimental Medicine, 2001, 194, 1339-1348.	8.5	111
89	Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11515-11520.	7.1	299
90	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Targeting Antigen to Endosomal/Lysosomal Compartments. Human Gene Therapy, 2001, 12, 235-252.	2.7	72
91	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen. Journal of Virology, 2001, 75, 2368-2376.	3.4	80

#	ARTICLE	IF	CITATIONS
92	Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens. <i>Journal of Immunology</i> , 2001, 167, 3936-3943.	0.8	40
93	Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses. <i>Journal of the National Cancer Institute</i> , 2001, 93, 998-1007.	6.3	28
94	A Phase I Trial of Intralesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma. <i>Human Gene Therapy</i> , 2001, 12, 1459-1480.	2.7	33
95	CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 5561-5566.	7.1	210
96	A Role for IFN- γ in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo. <i>Journal of Immunology</i> , 2002, 168, 4472-4479.	0.8	62
97	Improved Treatment of Pancreatic Cancer by IL-12 and B7.1 Costimulation: Antitumor Efficacy and Immunoregulation in a Nonimmunogenic Tumor Model. <i>Molecular Therapy</i> , 2002, 5, 405-412.	8.2	28
98	Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: prevention of parental tumor growth in the subcutaneous environment. <i>Journal of Neurosurgery</i> , 2002, 97, 432-440.	1.6	2
99	Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells. <i>Journal of Experimental Medicine</i> , 2002, 195, 343-351.	8.5	877
100	Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. <i>Blood</i> , 2002, 99, 2146-2153.	1.4	44
101	EBV Persistence in Vivo. , 2002, , 207-229.		0
102	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 11-18.	1.0	12
103	Application of Candida solubilized cell wall β -glucan in antitumor immunotherapy against P815 mastocytoma in mice. <i>International Immunopharmacology</i> , 2002, 2, 59-67.	3.8	23
104	Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy. , 2002, , 31-52.		9
105	Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. <i>Experimental Hematology</i> , 2002, 30, 195-204.	0.4	25
106	Cancer vaccines: dream, reality, or nightmare?. <i>Clinical and Experimental Medicine</i> , 2002, 2, 109-118.	3.6	8
107	The innate immune response to tumors and its role in the induction of T-cell immunity. <i>Immunological Reviews</i> , 2002, 188, 9-21.	6.0	194
108	Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor. <i>Journal of Neuro-Oncology</i> , 2002, 60, 13-23.	2.9	10
109	New Designs for Cancer Vaccine and Artificial Veto Cells: An Emerging Palette of Protein Paints. <i>Immunologic Research</i> , 2003, 27, 565-574.	2.9	12

#	ARTICLE	IF	CITATIONS
110	Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 162-170.	4.2	13
111	Enhancing CTL responses to melanoma cell vaccines in vivo : synergistic increases obtained using IFN- γ primed and IFN- γ treated B7-1 + B16-F10 melanoma cells. <i>Immunology and Cell Biology</i> , 2003, 81, 459-471.	2.3	18
112	Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response. <i>Immunology</i> , 2003, 110, 474-481.	4.4	7
113	Immunotherapy and prostate cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 199-209.	7.7	34
114	Intra-Lesional rF-B7.1 Versus rF-TRICOM Vaccine in the Treatment of Metastatic Cancer. <i>Human Gene Therapy</i> , 2003, 14, 803-827.	2.7	12
115	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. <i>British Journal of Cancer</i> , 2003, 88, 1527-1536.	6.4	31
116	Natural Killer Cells and Cancer. <i>Advances in Cancer Research</i> , 2003, 90, 127-156.	5.0	360
117	Suppression of peritoneal metastasis in human gastric carcinoma by enhanced immunogenicity of B7-1 transfection. <i>Oncology Reports</i> , 2004, 12, 53.	2.6	3
118	B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. <i>Clinical Cancer Research</i> , 2004, 10, 5094-5100.	7.0	633
119	CD80 gene therapy for lymph node involvement by gastric carcinoma. <i>International Journal of Oncology</i> , 2004, 25, 1319.	3.3	1
120	Immunogenicity of Human Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 69-80.	3.8	48
121	B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma. <i>International Journal of Cancer</i> , 2004, 110, 61-69.	5.1	15
122	Identification of a Circulating Soluble Form of CD80: Levels in Patients with Hematological Malignancies. <i>Leukemia and Lymphoma</i> , 2004, 45, 2111-2118.	1.3	38
123	Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B7-1 gene transfection. <i>Journal of Surgical Research</i> , 2004, 122, 89-95.	1.6	11
124	Vaccine Therapy for Murine Glioma Using Tumor Cells Genetically Modified to Express B7.1. <i>Neurosurgery</i> , 2004, 54, 182-190.	1.1	9
125	Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. <i>Blood</i> , 2004, 103, 4353-4361.	1.4	37
126	Induction of T-Cell Apoptosis in Rats by Genetically Engineered Glioma Cells Expressing Granulocyte-Macrophage Colony-Stimulating Factor and B7.1. <i>Clinical Cancer Research</i> , 2005, 11, 1639-1649.	7.0	5
127	Genetically Engineered Myeloma Cell Vaccine. , 2005, 113, 235-244.		0

#	ARTICLE	IF	CITATIONS
129	Liposomal vaccinesâ€”targeting the delivery of antigen. <i>Methods</i> , 2006, 40, 39-52.	3.8	80
130	Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1. , 2006, 47, 4607.		14
131	Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF- β combination therapy. <i>International Journal of Cancer</i> , 2006, 119, 2632-2641.	5.1	15
132	Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model. <i>Clinical Cancer Research</i> , 2006, 12, 5859-5868.	7.0	115
133	The Role of Structurally Conserved Class I MHC in Tumor Rejection: Contribution of the Q8 Locus. <i>Journal of Immunology</i> , 2006, 177, 2123-2130.	0.8	8
134	Costimulation, Coinhibition and Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 15-30.	1.6	86
135	General Principles of Tumor Immunotherapy. , 2007, , .		3
136	Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 58, 267-274.	2.0	103
137	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN γ . <i>International Journal of Cancer</i> , 2007, 121, 1282-1295.	5.1	16
138	Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1955-1965.	4.2	4
139	Signaling through CD80: an approach for treating lymphomas. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 969-979.	3.4	28
140	Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models. <i>Current Molecular Medicine</i> , 2008, 8, 68-75.	1.3	10
141	CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis. <i>Leukemia and Lymphoma</i> , 2008, 49, 1792-1799.	1.3	5
142	A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. <i>Medical Oncology</i> , 2014, 31, 60.	2.5	26
143	Concept of Reverse Costimulation and Its Role in Diseases. , 2015, , 45-81.		3
144	Costimulation in Lymphomas and Cancers. , 2015, , 185-254.		7
145	Mouse Model for Preâ€”Clinical Study of Human Cancer Immunotherapy. <i>Current Protocols in Immunology</i> , 2015, 108, 20.1.1-20.1.43.	3.6	23
146	Regulation of NKG2D ⁺ CD8 ⁺ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. <i>Onc Immunology</i> , 2016, 5, e1252012.	4.6	21

#	ARTICLE	IF	CITATIONS
147	Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. <i>Biomaterials</i> , 2016, 74, 231-244.	11.4	33
148	Evaluating the expression level of co-stimulatory molecules CD 80 and CD 86 in different types of colon polyps. <i>Current Research in Translational Medicine</i> , 2018, 66, 19-25.	1.8	6
149	Knockdown of LncRNA MALAT1 contributes to cell apoptosis via regulating NF- κ B/CD80 axis in neonatal respiratory distress syndrome. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 104, 138-148.	2.8	17
150	SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes. <i>Frontiers in Immunology</i> , 2018, 9, 776.	4.8	17
151	Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. <i>Nature Reviews Immunology</i> , 2021, 21, 257-267.	22.7	122
152	Triggering of Natural Killer Cell Mediated Cytotoxicity by Costimulatory Molecules. <i>Current Topics in Microbiology and Immunology</i> , 1998, 230, 53-61.	1.1	12
153	POTENT ANTITUMOR EFFECTS OF CD154 TRANSDUCED TUMOR CELLS IN EXPERIMENTAL BLADDER CANCER. <i>Journal of Urology</i> , 2001, , 1093-1097.	0.4	4
154	Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. <i>Journal of Virology</i> , 1997, 71, 4882-4891.	3.4	282
155	The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. <i>Journal of Clinical Investigation</i> , 2000, 105, 1227-1232.	8.2	64
156	Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses. <i>PLoS ONE</i> , 2013, 8, e62924.	2.5	92
157	<i>In situ</i> expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. <i>World Journal of Gastroenterology</i> , 2003, 9, 1370.	3.3	24
158	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	1.1	89
159	Cancer-Specific Vaccines. , 2008, , 649-669.		1
160	Failure of Tumor Immunity Resulting from Inaccessibility of Activated Lymphocytes to Solid Tumors. , 1998, , 73-84.		0
161	Interleukin-12-Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. <i>Blood</i> , 1998, 91, 196-206.	1.4	11
162	Tumour immunology. , 1998, , 73-87.		1
163	SELF-NONSELF DISCRIMINATION OF ANTI-TUMOR IMMUNE RESPONSES. , 1998, , 123-143.		0
164	Vaccines using Gene-Modified Tumor Cells. , 1999, , 283-298.		0

#	ARTICLE	IF	CITATIONS
165	Immunomodulatory Molecules of the Immune System. , 2007, , 67-121.		0
167	Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Molecular Medicine, 1996, 2, 545-55.	4.4	18
174	The Role of B7-1 and B7-2 Costimulation for the Generation of CTL Responses In Vivo. Journal of Immunology, 1998, 161, 2740-2745.	0.8	61
175	Host B7-1 and B7-2 Costimulatory Molecules Contribute to the Eradication of B7-1-Transfected P815 Tumor Cells Via a CD8+ T Cell-Dependent Mechanism. Journal of Immunology, 1999, 162, 4817-4823.	0.8	21
176	The Tumorigenicity of IL-2 Gene-Transfected Murine M-3D Melanoma Cells Is Determined by the Magnitude and Quality of the Host Defense Reaction: NK Cells Play a Major Role. Journal of Immunology, 1999, 162, 6650-6657.	0.8	14
177	Differential Coupling of Second Signals for Cytotoxicity and Proliferation in CD8+ T Cell Effectors: Amplification of the Lytic Potential by B7. Journal of Immunology, 1999, 163, 2999-3006.	0.8	29
178	NK Cell Triggering by the Human Costimulatory Molecules CD80 and CD86. Journal of Immunology, 1999, 163, 4207-4212.	0.8	80
179	VIP and PACAP Differentially Regulate the Costimulatory Activity of Resting and Activated Macrophages Through the Modulation of B7.1 and B7.2 Expression. Journal of Immunology, 1999, 163, 4213-4223.	0.8	55
180	Apoptosis of a Human Melanoma Cell Line Specifically Induced by Membrane-Bound Single-Chain Antibodies. Journal of Immunology, 1999, 163, 3948-3956.	0.8	9
181	Introduction on Immune Checkpoints in Cancer. , 2023, , 1-19.		0